Major depressive disorder (MDD) is a prevalent and debilitating mental illness that affects millions globally. Traditionally, the pathophysiology of MDD was thought to be due primarily neurotransmitter imbalances. However, emerging research highlights the role of neuroinflammation in MDD pathogenesis. Elevated levels of pro-inflammatory cytokines, microglial activation, and blood-brain barrier dysfunction have been implicated in the etiology of MDD. Additionally, biomarkers such as C-reactive protein and neuroimaging findings further support the neuroinflammatory hypothesis. This growing body of evidence has led to increased interest in novel treatment approaches, including anti-inflammatory medications and lifestyle interventions, as potential therapeutic strategies. While selective serotonin reuptake inhibitors remain the primary treatment for MDD, their limitations necessitate alternative approaches. Future research should focus on refining diagnostic biomarkers, elucidating causative mechanisms, and developing targeted anti-inflammatory therapies to enhance treatment efficacy. Understanding the relationship between neuroinflammation and MDD may lead to the development of more personalized and effective interventions.
Sophia M Valerino (Sun,) studied this question.